Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Mar 16:44:134.
doi: 10.11604/pamj.2023.44.134.32404. eCollection 2023.

Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials

Hammad Ali Fadlalmola  1 , Amal Mohammed Elhusein  2 , Khaled Mohammed Al-Sayaghi  1 , Muayad Saud Albadrani  3 , Duggahatti Veerabhadra Swamy  2 , Daniel Mon Mamanao  1 , Ehab Ibrahim El-Amin  4 , Salma Elhadi Ibrahim  5 , Siddiqa Mohammed Abbas  5
Affiliations
Meta-Analysis

Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials

Hammad Ali Fadlalmola et al. Pan Afr Med J. .

Abstract

Polycystic ovarian syndrome (PCOS) is a metabolic and hormonal condition affecting women of a reproductive age. It causes an abnormal menstrual cycle, anovulation, infertility, acne, hirsutism, obesity, hyperlipidemia, and cardiovascular disorders. Because resveratrol decreases testosterone levels, it may be of value in treating PCOS. We aimed to evaluate the efficacy of resveratrol in treating women with PCOS. We searched for randomized clinical trials (RCTs) in PubMed, Cochrane CENTRAL, Scopus and Web of Science. With 95% confidence intervals, the data was retrieved and analyzed as a mean difference (MD) or a standardized mean difference (SMD). Four RCTs with 218 women were included in the analysis. Resveratrol significantly reduced testosterone (SMD = -0.40; 95% CI [-0.71, -0.10], P = 0.009), luteinizing hormone (LH) (SMD = -0.32; 95% CI [-0.62, 0.01], P = 0.04), and dehydroepiandrosterone sulfate (DHEAS) (MD = -0.85; 95% CI [-1.25, -0.45], P < 0.0001) compared with the placebo. Resveratrol is effective in treating women with PCOS due to reducing the levels of testosterone, LH, and DHEAS. In combination with other treatments, especially for hyperlipidemia, resveratrol is beneficial for women diagnosed with PCOS.

Keywords: Meta-analysis; polycystic ovary syndrome; resveratrol; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
PRISMA flow chart which summarizes the literature search, and number of the obtained records
Figure 2
Figure 2
summary of risk of bias for each included study
Figure 3
Figure 3
forest plot of laboratory tests (hormones) including total testosterone, FSH (mIU/mL), LH (mIU/mL), prolactin (ng/mL), TSH (mIU/mL), and DHEAS
Figure 4
Figure 4
forest plot of pregnancy occurrence including positive clinical pregnancy and positive chemical pregnancy
Figure 5
Figure 5
forest plot of lipid profiles including cholesterol (mg/dl), HDL-C (mg/dl), LDL-C (mg/dl), and triglycerides (mg/dl)
Figure 6
Figure 6
forest plot of other parameters including acne score, CRP, Insulin (mIU/mL), SHBG (nmol/L)
See this image and copyright information in PMC

References

    1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004 Jan;19(1):41–7. - PubMed
    1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007 Aug 25;370(9588):685–97. - PubMed
    1. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602–1618. - PMC - PubMed
    1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016 Jul;106(1):6–15. - PubMed
    1. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997 Jul;47(1):93–9. - PubMed